Empagliflozin reduced the risk of serious HF events and slowed eGFR decline in patients with HF and LVEF >40% regardless of baseline atrial fibrillation (interaction p = 0.99).
RCT
Does empagliflozin reduce serious HF events and slow eGFR decline in patients with HF and LVEF >40% with and without AF?
Empagliflozin effectively reduces serious heart failure events and slows renal function decline in patients with HFpEF, irrespective of the presence of atrial fibrillation.
AIMS: Atrial fibrillation/flutter (AF) is common in heart failure (HF) with preserved left ventricular ejection fraction (LVEF) and associated with worse outcomes. Empagliflozin reduces cardiovascular death or HF hospitalizations and slows estimated glomerular filtration rate (eGFR) decline in patients with HF and LVEF >40%. We aimed to assess the efficacy and safety of empagliflozin in improving outcomes in patients with HF and LVEF >40% with and without AF. METHODS AND RESULTS: /year, interaction p = 0.99) consistently in patients with and without AF. There was no increase in serious adverse events with empagliflozin versus placebo in patients with and without AF. CONCLUSIONS: In patients with HF and ejection fraction >40%, empagliflozin reduced the risk of serious HF events and slowed the eGFR decline regardless of baseline AF.
Filippatos et al. (Mon,) conducted a rct in Heart failure with preserved ejection fraction (LVEF >40%) with and without atrial fibrillation. Empagliflozin vs. Placebo was evaluated on Serious HF events and eGFR decline. Empagliflozin reduced the risk of serious HF events and slowed eGFR decline in patients with HF and LVEF >40% regardless of baseline atrial fibrillation (interaction p = 0.99).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: